An exploratory, open-label, dose, randomized trial to evaluate the ability of interleukin-2 (IL-2) [aldesleukin] to enhance HIV-specific immunity and influence the time to virologic relapse following withdrawal of potent antiretroviral therapy
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Aldesleukin (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 11 May 2012 Biomarkers information updated
- 10 May 2012 Actual end date May 2006 added as reported by ClinicalTrials.gov.
- 01 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.